Ronnsi Pharmaceutical

Ronnsi Pharmaceutical is a clinical-stage biotechnology company headquartered in Suzhou, China, dedicated to the discovery and development of innovative small molecule drugs. The company specializes in Targeted Protein Degradation (TPD) technologies, specifically focusing on the development of molecular glues and PROTACs to address previously undruggable targets. Their lead clinical candidate, RS1805, is a potent dual inhibitor of IDO1 and TDO designed to modulate the tumor microenvironment in advanced solid tumors. Ronnsi's proprietary platform enables the rapid identification of novel degraders for high-value targets in oncology and autoimmune diseases. By leveraging its expertise in medicinal chemistry and protein degradation, the company aims to provide transformative therapies for patients with significant unmet medical needs.